Meridian Bioscience, Inc. (VIVO)
A fully-integrated life science company whose principal businesses are development, manufacture, sale and distribution of diagnostic test kits; manufacture and distribution of bulk antigens and reagents; and manufacture of proteins and other biologicals.
Recs
With the upcoming vote on the "health reform plan", anybody that has anything to do with the health industries will suffer.
Recs
Awesome management
Recs
stockscouter 10, caps 5
Recs
msn screen:
5 year div. growth >= 20 %
annual eps growth >= 25%
debt/eq <= 0.5
current dividend >= 2.5%
Recs
Rapid testing products for medical conditions. Help keep malpractice rates down and is becoming cheaper. Get's the patient tested for certain illnesses quickly which means earlier treatment, which means cheaper for the medical company
Recs
Meridian Biosciences has been a great pick for me since 1989. It was one of the very first stocks I owned, and my second DRIP. It has very strong financials, an intelligent business plan, and many products in its pipeline. This is an excellent small-cap stock for getting in on the ground floor.
Recs
ibd
Recs
Well managed company whose products will only see more demand in coming years.
Recs
MERIDIAN IS POISED TO GAIN NEW BUSINESS UNFORTOLD
Recs
Vivo's services are always going to be necessary, the world is not exactly getting healthier and healthier. They presently have good numbers and have shown some growth in the past. I'm confident that this is one of those stocks to watch.
Recs
excellent financials. high percentage of insider ownership
Recs
Boring but nasty problems in hospitals, clinics, etc will quietly drive demand. Speculative insurance against serious flu or ecoli breakouts.
Recs
Most robust point of care testing portfolio- growth not likely to slow much given the diverse lab tests available- life science sector should improve over time.
Recs
No debt-Large cash flow -bright future
Recs
Testing out a portfolio of smallish-cap 5-star stocks found using the CAPS screener. All picks have at least 50 allstars backing them, which should be enough to minimize star rating fluctuations. It's only been about a week, and I expect a LOT of volatility, but I have high hopes for market beating performance. Time will tell...
Recs
oversold and undervalued after barley missing eps in qtr
Recs
Increase in visibility and spending in healthcare industry secondary to recent press about biosurveillance
Recs
400% PLUS RETURN IN 3 YEARS-WHAT ELSE CAN I TELL YOU--HAS 1.5 FOR 1 SPLIT TWICE--HOW CAN IT NOT BE A FAVORITE--20% ANNUAL GROWTH RATES
Recs
Great cash flow and great management equal great overall performance. values its shareholders and constantly progressing in the industry. GREAT VALUE!
Recs
Consistently coming out with new diagnostic tests for key organisms/viruses including E.coli, H pylori, influenza, RSV. Becoming a big name in the diagnostic market and strong earnings growth likely to continue in the short-term. Late flu season this year may give earnings a boost in early 2008.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 61 1 2 3 4 Next »